IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38147-0039

Applicant:

Yanina ROZENBERG et al.

Confirmation No.: 2364

Appl. No.:

10/049,871

Group Art Unit: 1632

Filing

October 3, 2003

Examiner: TO BE ASSIGNED

Date: Title:

TARGETED ARTIFICIAL GENE DELIVERY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a prima facie prior art reference against the claims of the present application.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

U.S. Serial No.: 10/049,871



Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: May 25, 2005

HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, DC 20006

Telephone: (202) 912-2000 Facsimile: (202) 912-2020

Paul M. Booth

Registration No. 40,244 Attorney for Applicant Customer No. 26633

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			ARI	Complete if Known	
		TRA	DEN	Application Number	10/049,871
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	October 3, 2003
				First Named Inventor	Yanina Rozenberg et al.
				Art Unit	1632
				Examiner Name	To Be Assigned
Sheet	1	of	1	Attorney Docket Number	38147-0039

		· · · · · · · · · · · · · · · · · · ·	
		NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
	1.	HONG, et al., Chinese Medical Journal, 108(5): 332-337, 1995.	
	2.	HUANG, Biochemistry, Vol. 8, No. 1, pp. 344-351 (1969).	
	3.	MARUYAMA, et al., Biochimica et Biophysica Acta, 1234, pp. 74-80, (1995).	
	4.	SCHOEPFER, et al., Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 2865-2870 (1998).	
	5.	SZOKA, et al., Biochimica et Biophysica Acta, 601, pp. 559-571 (1980).	ĺ
	6.	TORCHILIN, et al., Journal of Pharmaceutical Sciences, Vol. 84, No. 9, pp. 1049 - 1053 (1995).	
	7.	USTER et al., FEBS Letters, 386:243-246 (1996).	
	8.	ZALIPSKY, et al., Journal of Pharmaceutical Sciences, Vol. 85, No. 2, pp. 133-137 (1996).	
-	-		
			i .
	į.		
_			ļ
			ļ

		, W. S.
Examiner	Date	
Signature	Considered	

*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.